Cefepime versus ceftazidime in the treatment of lower respiratory tract infections
Related Experiment Videos
Abstract:
The objective of the study was to compare the safety and efficacy of cefepime and ceftazidime in the treatment of community acquired lower respiratory tract infections of moderate intensity. Eighty-six patients were randomized at a 2:1 ratio to receive respectively cefepime 1 g b.i.d. or ceftazidime 1 g t.i.d. The drugs were well tolerated and the occurrence of adverse events in each group was comparable. The rates of satisfactory clinical response were 96% (49/51) for cefepime and 89% (24/27) for ceftazidime. A total of 73 pathogens were isolated and pathogen eradication rates were 98% and 96% respectively for the cefepime and ceftazidime treatment groups. In conclusion, the data confirmed that cefepime could be a good alternative to ceftazidime.
Insights
Cefepime and ceftazidime showed comparable safety and efficacy in treating moderate community-acquired lower respiratory tract infections. Cefepime demonstrated high clinical response and pathogen eradication rates, suggesting it as a viable alternative.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Community-acquired lower respiratory tract infections (LRTI) pose a significant public health challenge.
- Antibiotic resistance necessitates the evaluation of effective treatment options for LRTI.
- Cefepime and ceftazidime are broad-spectrum cephalosporins used in treating bacterial infections.
Purpose of the Study:
- To compare the safety and efficacy of cefepime versus ceftazidime.
- To evaluate treatment outcomes for community-acquired lower respiratory tract infections of moderate intensity.
Main Methods:
- A randomized controlled trial involving 86 patients with moderate community-acquired LRTI.
- Patients were assigned to receive either cefepime (1 g b.i.d.) or ceftazidime (1 g t.i.d.) in a 2:1 ratio.
- Safety was assessed by monitoring adverse events, and efficacy was determined by clinical response and pathogen eradication rates.
Main Results:
- Both cefepime and ceftazidime were well-tolerated, with comparable rates of adverse events.
- Satisfactory clinical response rates were 96% for cefepime and 89% for ceftazidime.
- Pathogen eradication rates were high for both groups: 98% for cefepime and 96% for ceftazidime.
Conclusions:
- Cefepime demonstrated comparable safety and efficacy to ceftazidime in treating moderate community-acquired LRTI.
- Cefepime presents a favorable alternative treatment option for these infections.
- Further research may explore cefepime's role in broader respiratory tract infections.